[go: up one dir, main page]

UY40374A - Inhibidores de inflamasoma nlrp3 - Google Patents

Inhibidores de inflamasoma nlrp3

Info

Publication number
UY40374A
UY40374A UY0001040374A UY40374A UY40374A UY 40374 A UY40374 A UY 40374A UY 0001040374 A UY0001040374 A UY 0001040374A UY 40374 A UY40374 A UY 40374A UY 40374 A UY40374 A UY 40374A
Authority
UY
Uruguay
Prior art keywords
nlrp3
inhibitors
inflamasome
nlrp3 inflamasome
relates
Prior art date
Application number
UY0001040374A
Other languages
English (en)
Inventor
Xiaobin Ge
Henri Mattes
Zhicong Shi
Mei Xia
Ning Ye
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY40374A publication Critical patent/UY40374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de piridazin–3–ilo fenol de fórmula (I), en donde R1, R2, R3, R4 y R5 se definen en el presente documento, que inhiben la actividad del inflamasoma de la proteína 3 del receptor tipo NOD (NLRP3). La invención se refiere adicionalmente a los procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.
UY0001040374A 2022-08-03 2023-07-27 Inhibidores de inflamasoma nlrp3 UY40374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370300P 2022-08-03 2022-08-03
CN2023097282 2023-05-30

Publications (1)

Publication Number Publication Date
UY40374A true UY40374A (es) 2024-02-15

Family

ID=87580191

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040374A UY40374A (es) 2022-08-03 2023-07-27 Inhibidores de inflamasoma nlrp3

Country Status (19)

Country Link
US (2) US20240067627A1 (es)
EP (1) EP4565326A1 (es)
JP (1) JP2025525866A (es)
KR (1) KR20250043519A (es)
CN (1) CN119677725A (es)
AR (1) AR130094A1 (es)
AU (1) AU2023318764A1 (es)
CA (1) CA3262660A1 (es)
CL (1) CL2025000285A1 (es)
CO (1) CO2025002057A2 (es)
CR (1) CR20250063A (es)
DO (1) DOP2025000013A (es)
IL (1) IL318533A (es)
MA (1) MA71689A (es)
MX (1) MX2025001273A (es)
PE (1) PE20251255A1 (es)
TW (1) TW202406550A (es)
UY (1) UY40374A (es)
WO (1) WO2024028782A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510997A1 (fr) 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
FR2663326B2 (fr) 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8338591B2 (en) 2004-05-08 2012-12-25 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
AU2010309788A1 (en) 2009-10-20 2012-04-05 Novartis Ag Glycoside derivative and uses thereof
BR112012033253A2 (pt) 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP2014517016A (ja) 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
AU2014256633B2 (en) 2013-04-25 2017-02-02 Beone Medicines I Gmbh Fused heterocyclic compounds as protein kinase inhibitors
EA030430B1 (ru) 2013-11-05 2018-08-31 Новартис Аг Композиции и способы модуляции фарнезоидных х-рецепторов
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
BR112016012794A2 (pt) 2013-12-05 2017-08-08 Acerta Pharma Bv Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
AP2016009301A0 (en) 2013-12-20 2016-06-30 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
WO2015175487A1 (en) 2014-05-13 2015-11-19 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN103965169A (zh) 2014-05-30 2014-08-06 彭正中 一种化合物及其制备方法与用途
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
LT3461821T (lt) 2014-10-24 2020-08-10 Bristol-Myers Squibb Company Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai
MA41256B1 (fr) 2014-12-24 2021-02-26 Principia Biopharma Inc Dosage spécifique de site d'un inhibiteur de btk
CA2973873A1 (en) 2015-01-20 2016-07-28 Merial, Inc. Anthelmintic compounds, compositions and method of using thereof
US20180008629A1 (en) 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
SI3578547T1 (sl) 2015-02-16 2021-09-30 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
TWI810582B (zh) 2015-06-03 2023-08-01 美商普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
WO2017059702A1 (en) 2015-10-09 2017-04-13 Acea Biosciences, Inc Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
KR20250133463A (ko) 2015-11-04 2025-09-05 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 암 치료하는 방법
ES2879995T3 (es) 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3372607B1 (en) 2016-01-05 2021-04-28 Jiangsu Hengrui Medicine Co. Ltd. Crystalline form of btk kinase inhibitor and preparation method thereof
CA3011465A1 (en) 2016-01-15 2017-07-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
AU2018284853A1 (en) 2017-06-14 2019-12-19 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
CA3067410A1 (en) 2017-07-07 2019-01-10 Inflazome Limited Novel sulfonamide carboxamide compounds
CN110914258A (zh) 2017-07-14 2020-03-24 先天肿瘤免疫公司 Nlrp3调节剂
IL273741B (en) 2017-08-04 2022-09-01 Skyhawk Therapeutics Inc Methods and compositions for fusion modulation
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CN111373057A (zh) 2017-09-25 2020-07-03 斯基霍克疗法公司 用于筛选和鉴定剪接调节剂的方法和组合物
CA3078565A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
BR112020008981A2 (pt) 2017-11-09 2020-11-17 Inflazome Limited novos compostos de sulfonamida carboxamida
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
US11530207B2 (en) 2018-04-10 2022-12-20 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
WO2019207538A1 (en) 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US20230107277A1 (en) * 2020-03-27 2023-04-06 Astellas Pharma Inc. Substituted pyridazine compound
US20230348437A1 (en) * 2020-07-02 2023-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
US20240391895A1 (en) * 2020-12-25 2024-11-28 Tuojie Biotech (Shanghai) Co., Ltd. Pyridazine-containing compound and medicinal use thereof
CN116867769A (zh) * 2021-02-08 2023-10-10 南京明德新药研发有限公司 取代的哒嗪苯酚类衍生物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Also Published As

Publication number Publication date
US20240067627A1 (en) 2024-02-29
DOP2025000013A (es) 2025-02-28
WO2024028782A1 (en) 2024-02-08
US20250034114A1 (en) 2025-01-30
KR20250043519A (ko) 2025-03-28
CN119677725A (zh) 2025-03-21
MX2025001273A (es) 2025-03-07
EP4565326A1 (en) 2025-06-11
CR20250063A (es) 2025-03-27
JP2025525866A (ja) 2025-08-07
TW202406550A (zh) 2024-02-16
PE20251255A1 (es) 2025-05-06
IL318533A (en) 2025-03-01
CO2025002057A2 (es) 2025-03-06
US12378222B2 (en) 2025-08-05
CA3262660A1 (en) 2024-02-08
CL2025000285A1 (es) 2025-06-13
AU2023318764A1 (en) 2025-01-09
MA71689A (fr) 2025-05-30
AR130094A1 (es) 2024-10-30

Similar Documents

Publication Publication Date Title
CL2021003012A1 (es) Inhibidores del inflamasoma nlrp3
CL2024000552A1 (es) Inhibidores de nlrp3
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
CO2025002057A2 (es) Inhibidores de inflamasoma nlrp3
CR20250413A (es) Compuestos de pirido[4,3–d]pirimidina
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CO2024011162A2 (es) Inhibidores de nlrp3
MX2025002086A (es) Inhibidores novedosos de inflamasoma nlrp3
MX2021008426A (es) Nuevos derivados de sulfonilurea sustituida.
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
BR112022018996A2 (pt) 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52".
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados
TH2101007071A (th) ตัวยับยั้งอินแฟลมมาโซม nlrp3
AR134411A1 (es) Compuestos de uracilo
MX2025003933A (es) Formas de derivados del carbamato y usos relacionados
AR132037A1 (es) Derivados de piridazinil amino como inhibidores del receptor alk5